Eyepoint Pharmaceuticals (NASDAQ:EYPT) Price Target Raised to $55.00 at Cantor Fitzgerald

Posted by George Bondi on Aug 6th, 2026

Eyepoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) had its price target lifted by investment analysts at Cantor Fitzgerald from $47.00 to $55.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Cantor Fitzgerald’s target price would indicate a potential upside of 348.98% from the company’s previous close.

A number of other research firms have also commented on EYPT. Royal Bank Of Canada lowered their price target on shares of Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. HC Wainwright lowered their target price on shares of Eyepoint Pharmaceuticals from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday. Guggenheim reiterated a “buy” rating and issued a $68.00 price target on shares of Eyepoint Pharmaceuticals in a research note on Wednesday, June 24th. Stifel Nicolaus initiated coverage on Eyepoint Pharmaceuticals in a research note on Thursday, July 16th. They set a “buy” rating and a $40.00 price objective on the stock. Finally, Chardan Capital upped their target price on Eyepoint Pharmaceuticals from $29.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $44.38.

Read Our Latest Report on EYPT

Eyepoint Pharmaceuticals Stock Up 5.0%

Shares of EYPT stock opened at $12.25 on Thursday. Eyepoint Pharmaceuticals has a 12-month low of $9.51 and a 12-month high of $19.11. The firm has a 50 day moving average price of $13.12 and a two-hundred day moving average price of $13.79. The company has a market capitalization of $1.03 billion, a PE ratio of -3.50 and a beta of 1.76.

Eyepoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($1.00) by ($0.09). Eyepoint Pharmaceuticals had a negative return on equity of 110.54% and a negative net margin of 3,566.63%.The firm had revenue of $0.51 million for the quarter, compared to analyst estimates of $0.39 million. As a group, research analysts expect that Eyepoint Pharmaceuticals will post -3.3 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. KBC Group NV bought a new stake in Eyepoint Pharmaceuticals during the first quarter worth $29,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Eyepoint Pharmaceuticals by 51.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock valued at $74,000 after purchasing an additional 1,358 shares during the last quarter. Russell Investments Group Ltd. bought a new position in shares of Eyepoint Pharmaceuticals in the 3rd quarter valued at $76,000. Tower Research Capital LLC TRC raised its holdings in shares of Eyepoint Pharmaceuticals by 218.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company’s stock worth $82,000 after buying an additional 5,967 shares in the last quarter. Finally, California State Teachers Retirement System raised its holdings in shares of Eyepoint Pharmaceuticals by 20.6% during the 4th quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock worth $85,000 after buying an additional 794 shares in the last quarter. 99.41% of the stock is owned by institutional investors.

Eyepoint Pharmaceuticals Company Profile

(Get Free Report)

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.